Cancer Vaccine
Anaplastic lymphoma kinase is antigen for immune interventions
Published in Cancer Weekly, March 28th, 2006
According to a study from Italy, "Anaplastic lymphoma kinase (ALK) oncogenic fusion proteins, expressed in about 60% of anaplastic large cell lymphomas (ALCL), are tumor-specific molecular targets for such a malignancy. One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate whether ALK is a tumor-associated antigen suitable for immune interventions. The frequency and the functional phenotype of the anti-ALK CD8 precursor repertoire in freshly isolated peripheral blood mononuclear cells (PBMC) from healthy donors and ALK-positive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-03-28)
More Articles from Cancer Weekly
- Cancer Diagnostics
Intramucosal carcinoma and dysplasia detected by optical coherence tomography - Drug Development
N-(7-indazolyl)benzenesulfonamide derivatives identified as potent cell cycle inhibitors - Hepatocellular Cancer
Hepatocellular cancer survival linked to racial differences - Melanoma
Platelet-activating factor acts as promoter of melanoma metastasis - Adenocarcinomas
Fibroblast growth factor has oncogenic activity in ovarian endometrioid adenocarcinomas - Adenocarcinomas
Occupational physical activity linked to possible decreased adenocarcinoma risk - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
